ZINC OXIDE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	O.Zn
Molecular Weight	81.395
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[O-2].[ZnH2+2]

InChI

InChIKey=RNWHGQJWIACOKP-UHFFFAOYSA-N

InChI=1S/O.Zn/q-2;+2

HIDE SMILES / InChI

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Zn
Molecular Weight	65.3956
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783https://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459http://www.t3db.ca/toxins/T3D0733http://www.hmdb.ca/metabolites/HMDB01303http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/https://www.google.com/patents/US3130034
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6309044

Diammonium Zinc Disulfate is commonly used in fluid fertilizers. It is effective if properly applied in the soil (band application) and is less costly than chelate forms of zinc.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Streptococcus mutans 40 Target ID: CHEMBL612426 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 \| https://www.ncbi.nlm.nih.gov/pubmed/2913640	Inhibitor 7709
respiratory burst 38 Target ID: GO:0045730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8157083	Activator 1337
transformed cell apoptotic process 106 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Activator 1337
Methotrexate 37 Target ID: CHEMBL2364710 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Hydrolytic Enzyme 37
Target ID: ultraviolet B-induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/25947194	Interacts 316
T cell mediated immunity 39 Target ID: GO:0002456 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Activator 1337
Zinc transporter ZIP1 37 Target ID: Q9NY26 Gene ID: 27173.0 Gene Symbol: SLC39A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 994
Zinc transporter ZIP2 37 Target ID: Q9NP94 Gene ID: 29986.0 Gene Symbol: SLC39A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24077486	Binding Agent 994

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2501
Unknown 2501
Unknown 2501
Caries 42 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12599434 https://www.ncbi.nlm.nih.gov/pubmed/2913640 https://www.ncbi.nlm.nih.gov/pubmed/6353570	Preventing	Basic research	Unknown Approved Use Unknown
Ulcerative colitis 117 Sources: https://www.drugs.com/international/corticotropin-zinc-hydroxide.html https://www.ncbi.nlm.nih.gov/pubmed/13469787	Primary	Approved 8003	CORTROPHIN-ZINC Approved Use Treatment of ulcerative colitis and other colonic disorders. Launch Date -4.55328006E11
Zinc deficiency 38 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6383773	Primary	Preclinical	Unknown Approved Use Unknown
Acute myeloid leukemia 128 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24477783	Primary	Basic research	Unknown Approved Use Unknown
Breast cancer 411 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305766	Primary	Basic research	Unknown Approved Use Unknown
Renal insufficiency 39 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdf	Secondary	Approved 8003	VORAXAZE Approved Use Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate. Launch Date 1.32675836E12
Diaper dermatitis 37 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021026s000lbl.pdf	Primary	Approved 8003	VUSION Approved Use INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. Launch Date 1.140048E12
Poison Ivy dermatitis 37 Sources: https://www.drugs.com/cdi/zinc-oxide-cream.html	Primary	Approved 8003	ZINC OXIDE Approved Use Unknown
Gastrointestinal disorders 92 Sources: https://www.drugs.com/pro/zinc-sulfate-injection.html	Primary	Approved 8003	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Mucositis 38 Sources: https://clinicaltrials.gov/ct2/show/NCT01015183	Primary	Phase III 651	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Dysgeusia 37 Sources: https://clinicaltrials.gov/ct2/show/NCT00036881	Primary	Phase III 651	ZINC SULFATE Approved Use Unknown Launch Date 5.47171205E11
Unknown 2501

PubMed

Title	Date	PubMed
A medicated polycarboxylate cement to prevent complications in composite resin therapy.	1990 Jan	2404104
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.	1991 Apr 1	9996367
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.	1995 Nov 13	7488149
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.	2000 Sep	10978858
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.	2004	16145958
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.	2004 Jul 16	15131129
High-throughput computational and experimental techniques in structural genomics.	2004 Oct	15489337
Impact of the mother's zinc deficiency on the woman's and newborn's health status.	2005	16240669
Erythrocyte zinc content in critically ill patients.	2005	16176172
Zinc in attention-deficit/hyperactivity disorder.	2005 Aug	16190793
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.	2005 Aug	16042674
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.	2005 Nov-Dec	16277018
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.	2005 Sep 1	16118778
Effects of zinc supplementation in patients with type 1 diabetes.	2005 Summer	16034148
Characterization and inhibition of SARS-coronavirus main protease.	2006	16611148
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.	2006 Apr	16608609
Copper and zinc concentrations in serum of healthy Greek adults.	2006 Apr 15	15955548
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.	2006 Dec	17093223
Elevated cortical zinc in Alzheimer disease.	2006 Jul 11	16832080
The effect of Ramadan on maternal nutrition and composition of breast milk.	2006 Jun	16732795
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.	2006 May	16636303
Zinc homeostasis in aging: two elusive faces of the same "metal".	2006 Summer	16706668
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.	2009 Mar 28	19382294
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.	2010 Feb	19755143
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.	2010 Oct	20708676
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.	2011 Dec	21903158
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?	2011 Mar 1	21220601
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.	2011 Mar 21	21341804
Responses of human cells to ZnO nanoparticles: a gene transcription study.	2011 Nov	21769377
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.	2012 Feb	22112499
Glucarpidase for the treatment of life-threatening methotrexate overdose.	2012 Nov	23170306
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.	2013 Dec	23519475
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.	2013 Dec	24060544
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.	2013 Jul 31	23726862
Inorganic salts in atmospheric particulate matter: Raman spectroscopy as an analytical tool.	2013 Nov	23880412
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.	2013 Nov 25	24120544
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.	2014 Apr	24368203
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.	2014 Jan	23832296
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.	2014 Jul 1	24746987
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.	2014 Mar 3	24374571
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.	2014 May 16	24631018
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.	2014 May 16	24614525
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.	2015 Sep	25940351
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.	2015 Sep	25631103
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.	2016 Mar 5	26561748
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.	2016 Oct 1	27546855
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.	2016 Sep	26892107
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.	2016 Sep 21	27530867
Intense 2.7μm emission in Er³⁺ doped zinc fluoride glass.	2017 May 15	28214427

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:13:18 UTC 2021` Edited by `admin` on `Fri Jun 25 21:13:18 UTC 2021`
Record UNII	SOI2LOH54Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZINC OXIDE

Official Name

English

ZINC OXIDE COMPONENT OF VUSION

Common Name

English

ZINC OXIDE [WHO-DD]

Common Name

English

C.I. 77947

Common Name

English

ZINC OXIDE [USP-RS]

Common Name

English

ZINC WHITE

Common Name

English

ZINC (AS ZINC OXIDE) [VANDF]

Common Name

English

ZINC OXIDE COMPONENT OF CALAMINE

Common Name

English

CALAMINE COMPONENT ZINC OXIDE

Common Name

English

CI 77947

Official Name

English

C.I. PIGMENT WHITE 4

Common Name

English

ZINCUM OXYDATUM

Common Name

English

ZINC OXIDE NEUTRAL [USP MONOGRAPH]

Common Name

English

ZINC OXIDE [MART.]

Common Name

English

ZINC OXIDE EMULSION [VANDF]

Common Name

English

ZINC OXIDE [WHO-IP]

Common Name

English

ZINC PASTE [VANDF]

Common Name

English

ZINC OXIDE [HSDB]

Common Name

English

ZINC OXIDE [INCI]

Common Name

English

ZINC OXIDE [ORANGE BOOK]

Common Name

English

ZINC OXIDE [FCC]

Common Name

English

ZINC OXIDE [EP MONOGRAPH]

Common Name

English

ZINC OXIDE [II]

Common Name

English

ZINCI OXYDUM [WHO-IP LATIN]

Common Name

English

ZINC OXIDE [JAN]

Common Name

English

ZINC OXIDE [VANDF]

Common Name

English

CI 77947 [INCI]

Common Name

English

ZINC (AS OXIDE) [VANDF]

Common Name

English

VUSION COMPONENT ZINC OXIDE

Common Name

English

ZINC OXIDE [USP]

Common Name

English

ZINC PASTE

Common Name

English

ZINC OXIDE [MI]

Common Name

English

ZINCUM OXYDATUM [HPUS]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 178.3297